![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Gilead Enters Agreement to Acquire Nimbus Apollo for $1.2B
Gilead Enters Agreement to Acquire Nimbus Apollo for $1.2B
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
April 8, 2016
Gilead Sciences has entered into an agreement to acquire Nimbus Therapeutics subsidiary Nimbus Apollo and its acetyl-CoA carboxylase inhibitor program.
Under the agreement, Gilead will pay Nimbus $400 million upfront and up to $800 million in additional milestones.
Gilead will oversee development and commercialization of Nimbus’ ACC inhibitors, including NDI-010976, and other ACC inhibitors that treat nonalcoholic steatohepatitis, hepatocellular carcinoma and other conditions.
FDA granted NDI-010976 fast track status in February.
Upcoming Events
-
21Oct